Xenoendocrine disrupters-tiered screening and testing: Filling key data gaps

• Published in: Toxicology (Amsterdam) Vol. 181; pp. 371 - 382
• Main Authors: Gray, L.E., Ostby, J., Wilson, V., Lambright, C., Bobseine, K., Hartig, P., Hotchkiss, A., Wolf, C., Furr, J., Price, M., Parks, L., Cooper, R.L., Stoker, T.E., Laws, S.C., Degitz, S.J., Jensen, K.M., Kahl, M.D., Korte, J.J., Makynen, E.A., Tietge, J.E., Ankley, G.T.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Shannon Elsevier Ireland Ltd 27.12.2002; Amsterdam Elsevier Science
• Subjects: Animals; Antiandrogens; Biological and medical sciences; Biological Assay; Endocrine disruption; endocrine disruptors; Endocrine Glands - drug effects; Endocrine System Diseases - chemically induced; Endocrine System Diseases - pathology; Environmental pollutants toxicology; Estrogens; Freshwater; General aspects; Humans; Medical sciences; Toxicology; Toxicology - methods; United States; United States Environmental Protection Agency; Xenobiotics - toxicity; United States; Antiandrogens; Endocrine disruption; Estrogens; Bioassay; Toxicity; Chemical compound; Endocrine disruptor; Toxicity test; Medical screening; Investigation method; Animal; Detection; Comparative study
• ISSN: 0300-483X; 1879-3185
• DOI: 10.1016/S0300-483X(02)00469-9

The US Environmental Protection Agency (EPA) is developing a screening and testing program for endocrine disrupting chemicals (EDCs) to detect alterations of hypothalamic–pituitary–gonadal (HPG) function, estrogen (ER), androgen (AR) and thyroid hormone synthesis and AR and ER receptor-mediated effects in mammals and other animals. High priority chemicals would be evaluated in the Tier 1 Screening (T1S) battery and chemicals positive in T1S would then be tested (Tier 2). T1S includes in vitro ER and AR receptor binding and/or gene expression, an assessment of steroidogenesis and mammalian (rat) and nonmammalian in vivo assays ( Table 1). In vivo, the uterotropic assay detects estrogens and antiestrogens, while steroidogenesis, antithyroid activity, (anti)estrogenicity and HPG function are assessed in a ‘Pubertal Female Assay’. (Anti-) androgens are detected in the Hershberger Assay (weight of AR-dependent tissues in castrate-immature-male rats). Fish and amphibian assays also are being developed. The fathead minnow assay can identify EDCs displaying several mechanisms of concern, including AR and ER receptor agonists and antagonists and inhibitors of steroid hormone synthesis. An amphibian metamorphosis assay is being developed to detect thyroid-active substances. Several alternative mammalian in vivo assays have been proposed. Of these, a short-term pubertal male rat assay appears most promising. An in utero-lactational screening protocol also is being evaluated. For Tier 2, the numbers of endocrine sensitive endpoints and offspring (F1) examined in multigenerational tests need to be expanded for EDCs. Consideration should be given to tailoring T2, based on the results of T1S. Tier 1 and 2 also should examine relevant mixtures of EDCs. Toxicants that induce malformations in AR-dependent tissues produce cumulative effects even when two chemicals act via different mechanisms of action.